Catalyst Pharmaceuticals, Inc.
CPRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,472 | $1,787 | $1,923 | $700 |
| - Cash | $518 | $138 | $298 | $171 |
| + Debt | $3 | $4 | $4 | $4 |
| Enterprise Value | $1,958 | $1,652 | $1,628 | $532 |
| Revenue | $492 | $398 | $214 | $141 |
| % Growth | 23.5% | 85.9% | 52.1% | – |
| Gross Profit | $423 | $346 | $180 | $119 |
| % Margin | 86% | 86.9% | 83.9% | 84.5% |
| EBITDA | $233 | $120 | $103 | $53 |
| % Margin | 47.4% | 30.1% | 48.1% | 37.3% |
| Net Income | $164 | $71 | $83 | $39 |
| % Margin | 33.3% | 17.9% | 38.8% | 28% |
| EPS Diluted | 1.31 | 0.63 | 0.75 | 0.37 |
| % Growth | 107.9% | -16% | 102.7% | – |
| Operating Cash Flow | $240 | $144 | $116 | $60 |
| Capital Expenditures | -$1 | -$82 | -$0 | -$1 |
| Free Cash Flow | $239 | $62 | $116 | $59 |